Biologics in severe asthma: utilization patterns, causes for discontinuation and switches

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/32725
• EU PAS number:
  EUPAS32724
• Study ID:
  32725
• Official title and acronym:
  Biologics in severe asthma: utilization patterns, causes for discontinuation and switches
• DARWIN EU® study:
  No
• Study countries:
  Singapore

  United Kingdom
• Study description:
  To describe the use of biologics in patients with severe asthma, with respect to persistence and switch to another biologic, and how this relates to asthma outcomes.To describe the frequency, patterns, reasons and clinical outcomes for biologic treatment discontinuation and switching in a severe asthma cohort.To describe the demographical and clinical characteristics of severe asthma patients that discontinue or switch their biologic therapy, stratified by country.
• Study status:
  Planned

Research institutions and networks

Institutions

Optimum Patient Care (OPC)

United Kingdom

Networks

Optimum Patient Care (OPC) Network

United Kingdom (Northern Ireland)

Respiratory Effectiveness Group (REG)

Belgium

Denmark

France

Germany

Greece

Hungary

Italy

Netherlands

Spain

Sweden

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 20/12/2018

Study start date

Planned: 31/10/2019

Data analysis start date

Planned: 01/06/2019

Date of final study report

Planned: 01/10/2019

Sources of funding

Non-for-profit organisation (e.g. charity)

Pharmaceutical company and other private sector 

More details on funding

AstraZeneca, OPCG

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable